Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2

This study has been terminated.
Sponsor:
Collaborator:
VA Boston Healthcare System
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000310
First received: September 20, 1999
Last updated: January 13, 2017
Last verified: January 1996
  Purpose
The purpose of this study is to evaluate use of risperidone with cocaine abusers. Study measures incorporate an appropriate integration of behavioral and neurobiological indices.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: Risperidone
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Serotonin/Dopamine Antagonism of Cocaine Effect

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Urine toxicology for cocaine
  • Analog mood scales
  • POMS
  • EPS sx

Estimated Enrollment: 0
Study Start Date: January 1996
Study Completion Date: March 1996
Primary Completion Date: March 1996 (Final data collection date for primary outcome measure)
Detailed Description:
Risperidone in low doses is compared with placebo in a 6-week randomized trial. Subjects also receive supportive counseling. Outcome measure include rating of behavior, mood, drug abuse, global function, and urine toxicology.
  Eligibility

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Cocaine abuse or dependence

Exclusion Criteria:

Dependence on other drugs. Major psychiatric illness

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000310

Locations
United States, Rhode Island
Brown University School of Medicine
Providence, Rhode Island, United States, 2906
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
VA Boston Healthcare System
Investigators
Principal Investigator: Lawrence Price, M.D. Brown University
  More Information

ClinicalTrials.gov Identifier: NCT00000310     History of Changes
Other Study ID Numbers: NIDA-09330-2
R01-09330-2
Study First Received: September 20, 1999
Last Updated: January 13, 2017

Keywords provided by National Institute on Drug Abuse (NIDA):
cocaine dependence

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Risperidone
Dopamine
Serotonin
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Cardiotonic Agents
Sympathomimetics
Autonomic Agents
Protective Agents
Serotonin Antagonists
Serotonin Agents
Antipsychotic Agents
Tranquilizing Agents
Psychotropic Drugs

ClinicalTrials.gov processed this record on May 24, 2017